Previously, Farhat served as president & CEO of American Medical Systems, Inc., where he helped facilitate Boston Scientific (NYSE:BSX)’s $1.65 billion acquisition of the men’s and prostate health businesses. He has also held leadership positions with Baxter (NYSE:BAX), Medtronic (NYSE:MDT) and General Electric (NYSE:GE).
“Today marks a significant development for RTI’s future. We are pleased that Camille Farhat, an experienced leader with a laser customer focus and solid track record of driving highly effective operational performance in complex health care markets, has agreed to join RTI as our new CEO,” RTI chairman Curtis Selquist said in prepared remarks. “On behalf of the entire board, I would like to thank Robert Jordheim for his service as interim CEO. We are pleased that he will be returning to his role as our chief financial officer once Camille is on board. I also want to thank Wy Louw, who has been serving as interim CFO and will resume his controller responsibilities.”
“I am excited to have the opportunity to shape RTI’s strategic direction and return it to sustainable growth,” Farhat added. “The RTI leadership team, its talented employees and I will dedicate ourselves to developing successful strategies for each business area to ensure we are better addressing our patients’ critical needs and leading the industry in innovation and quality. In doing so, I am confident that we will advance RTI’s path to growth and success.”
The Alachua, Fla.-based company also said that its executive VP & chief scientific officer, Caroline Hartill, is leaving the company effective Jan. 31. The company plans to eliminate the position of CSO but Hartill could work as a consultant after her departure, according to regulatory filings.
Ex-FDA ‘Botox police’ chief joins DLA Piper
George Karavetsos, the former FDA Office of Criminal Investigations director, was named partner at DLA Piper’s litigation firm last week. Karavetsos left his post at the FDA at the beginning of January.
Karavetsos drew scrutiny last year after allegedly forcing members of the criminal investigations office to pursue mislabeled foreign-imported injectable drug cases at the expense of seemingly more important issues, earning the office under Karavetsos’ lead the name “Botox police.”
At DLA Piper, Karavetsos will advise the firm’s clients in the pharmaceutical, medical device, food, dietary supplement, tobacco and healthcare sectors.
“George has a very unique combination of white collar and FDA regulatory experience,” Loren Brown, co-chair of DLA Piper’s global and US litigation practices, said in prepared remarks. “We’re excited to add someone with George’s reputation and talents to our team, and he will immediately enhance our trial bench, white collar and investigations platform, and FDA regulatory practice.” Read more
Aurora Spine appoints new CFO
Aurora Spine (TSX:ASG.V) said it named Sarina Mason as its chief financial officer, effective Feb. 6., to replace Eric Fronk, who resigned from the company to pursue other opportunities. Read more
Senseonics promotes Jain as COO
Senseonics (NYSE:SENS) promoted Mukul Jain to the position of chief operating officer and also appointed Jain as the company’s principal operating officer, effective immediately. Read more
Bioventus names CCO
Bioventus said it named John Nosenzo as its chief commercial officer. Nosenzo will head global sales and distributor management, as well as global marketing for the active healing therapies business, according to the company. Read more
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.